MNAIMay 5, 2020

Computational modeling of Human-nCoV protein-protein interaction network

arXiv:2005.04108v18 citations
Originality Synthesis-oriented
AI Analysis

This work addresses the limited experimental data on Human-nCoV interactions for COVID-19 research, providing a computational framework to identify potential therapeutic targets, though it is incremental by building on existing SARS-CoV knowledge.

The study developed a computational model to predict Human-nCoV protein-protein interactions by leveraging SARS-CoV-Human interaction data, identifying key human spreader proteins for COVID-19 and validating the network with FDA-listed drugs, showing significant overlap with known drug targets.

COVID-19 has created a global pandemic with high morbidity and mortality in 2020. Novel coronavirus (nCoV), also known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), is responsible for this deadly disease. International Committee on Taxonomy of Viruses (ICTV) has declared that nCoV is highly genetically similar to SARS-CoV epidemic in 2003 (89% similarity). Limited number of clinically validated Human-nCoV protein interaction data is available in the literature. With this hypothesis, the present work focuses on developing a computational model for nCoV-Human protein interaction network, using the experimentally validated SARS-CoV-Human protein interactions. Initially, level-1 and level-2 human spreader proteins are identified in SARS-CoV-Human interaction network, using Susceptible-Infected-Susceptible (SIS) model. These proteins are considered as potential human targets for nCoV bait proteins. A gene-ontology based fuzzy affinity function has been used to construct the nCoV-Human protein interaction network at 99.98% specificity threshold. This also identifies the level-1 human spreaders for COVID-19 in human protein-interaction network. Level-2 human spreaders are subsequently identified using the SIS model. The derived host-pathogen interaction network is finally validated using 7 potential FDA listed drugs for COVID-19 with significant overlap between the known drug target proteins and the identified spreader proteins.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes